Smaller innovators with limited investment capacity may see the need to take a phase-by-phase approach to bringing their novel therapy to market. However, the right long-term CRO relationship can create a multi-phase strategy that will optimize investment and accelerate milestone advancement. This new white paper presents a vision for a CRO relationship that is strategic rather than simply transactional.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
